Last Friday the first update meeting at national level to take a global view of the healthcare situation and present the latest research data for Neurofibromatosis type 2 (NF2) took place at the IGTP. This pioneering event was organized by the members of the National Reference Centre in genetic neuro-cutaneous syndromes (Facomatosis), (CSUR) on the Can Ruti Campus and also included patients and families affected by the disease.
At the IGTP TODAY
To celebrate World Diabetes Day we will literally be talking about the illness at the IGTP; several members of the Immunology of Diabetes Group, which is led by Marta Vives-Pi and concentrates on research into diabetes type 1, will be taking part in talks and discussions in scientific and public forums during the next few days.
Researchers from the Germans Trias i Pujol Hospital and Institute have developed and successfully validated a new one-step screening method to diagnose active hepatitis C virus (HCV) infection in people who inject drugs, a main high risk group. The new method validated will permit better planning of future more effective actions to improve diagnostics and treatments for this vulnerable group. The study also estimated the prevalence of HCV infection in this community and showed that many people tested do not know that they are infected.
The IGTP promotes science for high-school students at the celebration of the 24th Science Week at Can Ruti
This week the IGTP and other centres hosted the “Can Ruti Open Door Session” within Science Week in Badalona; the Science Week is a national event organized by the Spanish Foundation for Science and Technology (FECYT). This year nearly 200 high school students from various educational centres have visited the research facilities at nine different organizations on the Can Ruti Campus and learned about studies taking place there.
On Friday 8 November the first of the series of popular science talks organized by the Friends of Can Ruti (Amics de Can Ruti) took place in the Joan Coromines Library in Masnou and the Sant Andreu Library in Llavaneres. This is the second series of informative talks and once again they are inspired by the topic of this year's TV3 Marathon, which is rare diseases. Professionals from the IGTP and the Germans Trias Hospital are taking part.
Researchers reveal how beta cells in the pancreas respond to an inflammatory environment and how this response is implicated in the risk of developing Type 1 diabetes
The results point to a much more active role for pancreatic beta cells in type 1 diabetes than previously appreciated and suggests a mechanism that may play a key role in other auto-immune diseases.
Yesterday evening the ceremony to present awards to the 43 projects that will receive funding for cancer research from the 2018 edition of the La Marató de TV3 and Catalunya Radio was held at the Academy of Medical Sciences. Three of the projects will be carried out under the leadership of Germans Trias professionals.
In 2017 the team designed and tested a gene panel, in collaboration with the ICO, to standardize and simplify genetic testing for hereditary cancer. In the current work the group has validated and extended the use of this panel in the routine genetic testing for different RASopathies. These are other genetic diseases caused by mutations in genes of the Ras/MAPK pathway for which patients exhibit an overlapping clinical presentation with NF1, especially in children.
In the context of research and especially in the case of research into rare diseases, the COST Action Projects (Cooperation in Science and Technology) are key to fostering transnational cooperation. This is the message that a group of Spanish scientists, which includes Dr Gisela Nogales, have sent in a letter recently published in The Lancet Neurology.
The world’s largest non-profit funder of type 1 diabetes Research provides half a million dollars for Spanish T1D scientists
The Juvenile Diabetes Research Foundation (JDRF) is supporting a team of scientists that includes a group at the IGTP, led from the Andalusian research centre Cabimer, in their search for a cure for type 1 diabetes (T1D). Researchers in the Immunology of Diabetes Group at the IGTP are participating in the project as expert immunologists as they have wide experience of immunotherapies for T1D.